What Is a TR4 Thyroid Nodule and What Does It Mean?

A TR4 thyroid nodule is one that scores in the “moderately suspicious” category of the ACR TI-RADS system, a standardized method radiologists use to evaluate thyroid lumps found on ultrasound. The label does not mean you have cancer. It means the nodule has enough worrisome-looking features on imaging that your doctor will likely recommend a biopsy, depending on its size. The reality is that the majority of TR4 nodules turn out to be benign, but the category exists because the risk of malignancy is high enough that ignoring it would be irresponsible.

How the Scoring System Works

When a radiologist examines a thyroid nodule on ultrasound, they evaluate five characteristics: the nodule’s internal composition (solid, cystic, or mixed), its echogenicity (how bright or dark it appears compared to surrounding tissue), its shape, the smoothness of its margins, and whether it contains certain types of calcifications. Each feature gets a point value, and the total determines the TI-RADS category. TR1 means the thyroid looks normal, TR2 is “not suspicious,” TR3 is “mildly suspicious,” TR4 is “moderately suspicious,” and TR5 is “highly suspicious.”

TR4 typically captures nodules that score between 4 and 6 points on the ACR system. These tend to be solid or mostly solid, darker than surrounding tissue on ultrasound, and may have irregular margins or small bright spots that could represent calcifications. No single feature automatically lands a nodule in TR4; it is the combination that matters. A nodule that is solid but otherwise unremarkable might score TR3, while one that is solid, dark, and has an irregular border crosses into TR4 territory.

What the Cancer Risk Actually Looks Like

The numbers vary across studies, and many systems further split the TR4 category into subcategories. One large study found cancer rates of about 12% in TR4A nodules, roughly 34% in TR4B, and around 67% in TR4C, compared with under 3% for TR3 and over 86% for TR5.¹ Those subcategories reflect a wide spectrum, and the jump from TR4A to TR4C is enormous. If your report just says “TR4” without a letter, it generally means your nodule sits somewhere in that moderately suspicious range, and the biopsy is what will clarify things.

A cross-sectional study examining nodules by both imaging and cytology found that about a fifth of TR4 nodules showed high-risk features on biopsy, while the rest did not.² Another study looking at the actual biopsy results of TR4 nodules found that nearly 79% had benign cytology.³ So while the risk is real enough to warrant investigation, the odds still favor a noncancerous result for most people in this category.

Why Biopsy Size Thresholds Matter

A TR4 label does not automatically mean you need a needle biopsy. The ACR TI-RADS guidelines pair each category with a size threshold: for TR4 nodules, a fine-needle aspiration biopsy is generally recommended if the nodule measures 1.5 centimeters or larger. Below that, many guidelines suggest follow-up ultrasound instead. The logic is that very small nodules, even if they turn out to be cancerous, tend to be low-risk thyroid cancers that grow slowly and rarely spread. Performing biopsies on every small TR4 nodule would generate a huge number of procedures for very little clinical benefit.

This is one of the most common sources of confusion. You might receive an ultrasound report that categorizes a nodule as TR4 and then says “no biopsy recommended” because the nodule is only 8 or 10 millimeters across. That can feel contradictory, but the category and the management recommendation are two separate decisions. The category tells you how suspicious the nodule looks; the size threshold tells you whether that level of suspicion warrants an invasive step right now or whether monitoring is safer.

What Happens During and After a Biopsy

Fine-needle aspiration is a quick office procedure. A thin needle, guided by ultrasound, draws a small sample of cells from the nodule. The pathologist then examines those cells and assigns a Bethesda category, which is a separate classification system specifically for biopsy results. Bethesda I means the sample was insufficient, Bethesda II means benign, and Bethesda VI means malignant. The categories in between represent degrees of uncertainty.

For TR4 nodules, a significant concordance has been found between the TI-RADS ultrasound category and the Bethesda biopsy category, meaning the imaging and the cell samples tend to agree on which nodules deserve concern.⁴ When the biopsy comes back benign (Bethesda II), that is usually the end of the road, though your doctor may recommend a repeat ultrasound in one to two years. When the biopsy result falls into one of the indeterminate categories, the path forward gets more nuanced.

When Biopsy Results Are Unclear

Bethesda III and IV are the indeterminate categories, meaning the cells do not look clearly benign or clearly malignant. This happens in a meaningful minority of biopsies, and it is particularly relevant for TR4 nodules because the imaging already raised a flag. In this situation, doctors have a few options: repeat the biopsy, proceed to diagnostic surgery, or order molecular testing.

Molecular testing analyzes the biopsy sample for genetic mutations associated with thyroid cancer. One institutional study found that when molecular testing was performed on indeterminate nodules scored TR4 or TR5, it was more likely to detect genetic changes suggestive of malignancy, which helped prioritize which patients actually needed surgery and which could safely be monitored.⁵ Molecular testing does not replace biopsy; it adds a layer of information when the biopsy alone cannot give a definitive answer.

Active Surveillance Instead of Immediate Surgery

Even when a TR4 or TR5 nodule is confirmed or strongly suspected to be malignant, immediate surgery is not always the recommendation. Active surveillance, which means regular ultrasound monitoring without intervening surgically, has become an accepted approach for certain small, low-risk thyroid cancers. The idea is that many papillary thyroid cancers grow so slowly that watching them closely is just as safe as removing them right away, and it avoids the risks and lifelong medication that come with thyroid surgery.

A multicenter study tracking highly suspicious thyroid nodules under active surveillance found that significant growth (a diameter increase of 3 millimeters or more) occurred in only about 3% of patients, regardless of whether the nodule was located in the thyroid’s isthmus or elsewhere.⁶ Volume increases were more common, with roughly a quarter of nodules growing by 50% or more in volume, but even that degree of growth did not necessarily change the outcome for patients. These findings support the growing confidence that surveillance is a viable alternative to surgery for selected cases.

Incidental Nodules and the Big Picture

Many thyroid nodules are discovered incidentally, meaning they show up on imaging done for a completely unrelated reason, like a CT scan of the neck or chest. A long-term follow-up study of incidental thyroid nodules found on CT scans reported a prevalence of about 11%, with a mean nodule size of roughly 17.5 millimeters. Despite decades of follow-up, no patients in that cohort developed clinically evident thyroid malignancy, and none died from thyroid cancer.⁷ Only a small fraction of those incidental nodules were even referred for ultrasound or biopsy. This is worth keeping in mind: thyroid nodules are extremely common, and the vast majority will never cause harm.

That said, an incidental nodule is not the same thing as a TR4 nodule. The TIRADS score exists precisely to sort the ocean of thyroid nodules into those that deserve attention and those that do not. A TR4 finding means yours has been flagged as potentially important, and following through with the recommended evaluation is sensible. But the backdrop is important: you are starting from a position where thyroid nodules as a whole are overwhelmingly benign.

Not All TIRADS Systems Are Identical

If you have read about TIRADS online, you may have noticed that the scoring and categories seem to differ depending on the source. That is because several different TIRADS systems exist worldwide. The ACR TI-RADS (American College of Radiology) is the most commonly used in the United States, but Europe uses EU-TIRADS, South Korea uses K-TIRADS, and China has C-TIRADS. They all aim to stratify thyroid nodules by cancer risk, but they weigh features somewhat differently and use different point cutoffs.

A comparative study found that ACR-TIRADS had the highest diagnostic accuracy among three major systems at about 63%, along with the best specificity at roughly 59%, meaning it was best at correctly identifying benign nodules as benign. K-TIRADS had the highest sensitivity at about 94%, meaning it was best at catching cancers, though at the cost of flagging more benign nodules for biopsy.⁸ EU-TIRADS fell between the two. The practical takeaway is that a “TR4” under ACR-TIRADS and a “TR4” under EU-TIRADS may not represent the same thing, so if your report uses a non-ACR system, ask your doctor which one they followed.

The Human Element and Radiologist Disagreement

One underappreciated reality is that different radiologists looking at the same nodule will not always assign the same TI-RADS score. A study measuring interobserver agreement across various TIRADS systems found moderate agreement at best, with scores in the range of 0.47 to 0.61 on a scale where 1.0 would mean perfect agreement.⁹ Agreement improved after specific training, but the scores still reflect the reality that evaluating ultrasound features involves subjective judgment. A nodule that one radiologist calls TR3 might be called TR4 by another.

This is not a failure of the system. Rather, it is an honest reflection of how visual interpretation works. If you have been told your nodule is TR4 and you feel uncertain, getting a second opinion on the imaging is a reasonable step. The biopsy, when indicated, provides a much more objective answer.

How Artificial Intelligence Is Changing the Process

Researchers are developing AI tools to assist radiologists in scoring thyroid nodules, partly to address the variability described above. One study found that an AI-optimized version of TI-RADS achieved a slightly higher area under the curve (a measure of diagnostic accuracy) than the standard ACR system, and it improved specificity from about 47% to 65% for expert readers. For non-expert radiologists, the AI system also raised average specificity, meaning fewer benign nodules were unnecessarily flagged as suspicious.¹⁰ The AI also simplified the scoring by assigning zero points to several features that turned out to contribute little diagnostic value.

Another study testing AI-based ultrasound image analysis for distinguishing suspicious from non-suspicious nodules reported a sensitivity of 71% and specificity of 53%.¹¹ Those numbers are not yet transformative on their own, but the direction of the research is toward AI serving as a second set of eyes, particularly in settings where radiologists may not have extensive thyroid-specific training. These tools are not yet standard in most clinics, but they are likely to become part of the workflow within the next several years.

Thyroid Nodule Evaluation in Children

The TIRADS systems were developed using adult data, and thyroid cancer behaves somewhat differently in children and adolescents. Thyroid nodules are less common in young people, but when they occur, they carry a higher rate of malignancy than in adults. This means the adult-based size thresholds for recommending biopsy may miss cancers in younger patients.

A study examining pediatric-specific biopsy cutoffs found that lowering the size threshold for category 4 nodules in children (to 0.5 cm with clinical risk factors and 1.5 cm without) improved sensitivity from 60% to 84% under ACR TI-RADS and reduced the rate of missed malignancies.¹² Similarly, research evaluating both ACR-TIRADS and C-TIRADS in adolescents found that modified approaches tailored to the younger population significantly outperformed standard adult guidelines, reducing unnecessary biopsies while catching more cancers.¹³ If your child has a TR4 nodule, it is worth discussing with a pediatric endocrinologist or a thyroid specialist experienced with younger patients, because the standard adult guidelines may not apply directly.

The Psychological Weight of a TR4 Finding

Reading “moderately suspicious” on a medical report is stressful, and research confirms that the psychological burden is real. A study exploring anxiety in patients with thyroid nodules found that specific ultrasound features, particularly irregular edges and extension toward or beyond the thyroid capsule, were linked to higher anxiety levels.¹⁴ This makes sense: these are precisely the features that push a nodule’s score into TR4 territory, so patients with higher-category nodules are more likely to experience anxiety about their diagnosis.

If you have received a TR4 result, it helps to anchor yourself to the numbers. Even in the moderately suspicious category, the majority of nodules are benign. The TIRADS system exists not to alarm you but to standardize how doctors decide who needs a biopsy and who can safely be monitored. The alternative, biopsying every nodule or none at all, would be worse for patients in every measurable way.

When Benign TR4 Nodules Still Need Treatment

Not all treatment for thyroid nodules is about cancer. A benign TR4 nodule can still cause problems if it is large enough to press on your windpipe, make swallowing uncomfortable, or create a visible bulge in your neck. Traditionally, the answer was surgery. But thermal ablation techniques, including radiofrequency ablation and microwave ablation, have emerged as minimally invasive alternatives.

Radiofrequency ablation studies have included nodules scored up to EU-TIRADS category 4, provided the biopsy confirmed they were benign.¹⁵ Microwave ablation has similarly shown substantial reductions in nodule volume along with improved symptom and cosmetic scores, with complications limited to occasional transient hoarseness and no significant impact on thyroid function.¹⁶ These procedures are performed under local anesthesia and typically allow same-day discharge. For someone with a confirmed-benign TR4 nodule that is causing symptoms, ablation can be a way to shrink the nodule without removing part or all of the thyroid gland.

The Cost of Getting It Right

One of the less-discussed benefits of the TIRADS system is economic. Before standardized scoring existed, the decision to biopsy a thyroid nodule depended heavily on individual physician judgment, which led to wide variation in practice. Some doctors biopsied almost everything; others watched and waited. Standardized risk stratification has been shown to reduce unnecessary biopsies, which in turn reduces psychological distress for patients and financial costs for health systems.¹⁷ One analysis estimated that strict adherence to ACR TI-RADS and ATA guidelines could save a regional health system up to $88,000 annually, based on just under 300 nodules examined.¹⁸

For you as an individual patient, the practical implication is that the TIRADS system is designed to be judicious. A TR4 designation with a recommendation against biopsy (because the nodule is too small) is not your doctor being negligent. It is the system working as intended, reserving invasive steps for the cases where the risk-benefit math tilts toward action. If the nodule grows on follow-up imaging, the recommendation can always be upgraded.